Clinical Trial Search

Primary: Standardized Uptake Value (SUV) in gm/ml Reported as Mean and Standard Deviation — 7.293; 5.157; 4.429; 2.357 gm/ml

Primary: ACTNOW! Clinical Trial Knowledge Assessment Score — 93.89; 93.58; 94.88; 97.88 score

Primary: Number of Participants Enrolled in Each Recruitment Arm — 182 Participants

Primary: Prevalence of Transthyretin Cardiac Amyloidosis (ATTR-CA) in Cohort of Caribbean Hispanics and Blacks With Heart Failure (HF) — 7.8; 0 percentage of participants

Primary: Biphasic Alcohol Effects Scale - Stimulation — 11.3; 3.9; 8.7; 3.2 units on a scale

Primary: Change Expectation for Pain Relief as Measured by EXPECT Scores — 0.19; 0.28 score on a scale

Primary: Change in Global Patient Treatment Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) — 59.9; 64.4 score on a scale — p=0.001

Primary: Plasma PTH Level — 58.29; 60.73; 57.88; 54.05 pg/ml

Primary: Number of Participants With Initiation of Formal Depression Treatment — 9; 36 Participants

Primary: Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 48 — 72.5; 69.6 percentage of participants

Primary: COVID-19 Vaccination Rate for Eligible Children — 21.3; 33.5; 16.4; 26.7 Percent of participants vaccinated

Primary: Urinary Phosphorus Excretion — 11 percentage of fractional excretion

Primary: The Frequencies of Paired Responses to Identical Questions on a Survey Administered at Two Timepoints: Before the Health Education Program (i.e., Baseline) and…

Primary: Composite Rate of Death, Myocardial Infarction (MI), and Target Vessel Revascularization (TVR) — 128; 120; 155; 99 Participants

Primary: Change in Self-reported Healthy Lifestyle Beliefs Timepoint 0 to Timepoint 3 — 59.044; 59.349; 64.972; 64.234 units on a scale — p=<0.001

Primary: The Number of Participants Reporting 7 Day Point Prevalence Abstinence — 54; 45 Participants

Primary: Micropore Closure Time — 44.1; 48.0; 66.5; 50.1 hours

Primary: Intention to Talk to Doctor About Colorectal Cancer Screening — 4.14; 4.0; 3.59; 3.48 units on a scale

Primary: Enrollment Rate — 8.87 percentage of individuals approached

Primary: Number of Completed Exit Interviews From Patients on Feasibility of Their Use of Their Narrative Integrated Into EHR — 20; 18 Participants

Primary: ApoB Levels in African American Men With Diabetes and Those Without. — 80; 65 mg/dL — p==0.002

Primary: Efficacy of the Dosing Algorithm in Achieving Total 25(OH)D as Measured by the Percentage of Participants Ending With Concentrations of 35-50 ng/mL — 61.3; 58.5; 47.6…

Primary: Intention to Talk to Doctor About Colorectal Cancer Screening — 11.42; 11.31; 11.87; 11.42 units on a scale

Primary: Number (Percentage) of Participants Requested to Participate in Saliva-based SARS-CoV-2 Antibody Testing — 175; 84; 121 Participants

Primary: Average Take-up of Preventive Services (Post-consultation) — 0.52; .71 score on a scale

Primary: SARS-CoV-2 Home-testing Kit Completion Active vs. Passive Arms — 75; 94; 57; 42 Participants — p=0.04

Primary: Percent of Participants With A1C < 8% — 33; 34 percent of participants

Primary: Verbal Dominance — 2.65; 2.57; 2.10; 1.74 ratio — p=0.34

Primary: Percentage of Participants Who Are Screened for All Conditions — 25.18; 8.16; 32.63; 15.79 Percentage of participants

Primary: Number (%) of Subjects With Drug-related Adverse Events — 28.0; 51.9; 33.3; 92.6 Percentage of participants